In a case of a thyroid carcinoma with unusual morphology and absence of BRAFV600E and RAS mutations (assessed by IHC or targeted genetic testing), a broader NGS panel that includes capacity to detect NUTM1 fusions may be considered in the workup of the tumor. This evidence concerns the gene NUTM1 and thyroid gland carcinoma.